Skip to main content
STLN logo

STLN · Starling Oncology, Inc. · Documents

Track STLN — free
$3.26 +0.06 (+1.88%) Play latest call Q2 2026 earnings call transcript
Market Cap
$326.37M
Shares
101.99M
Volume · Nov 18 4.68M Avg daily vol (3M) 2.45M

The company's filings, earnings calls and investor events, most recent first. Search and read these filings from Claude or ChatGPT with the SEC filings MCP server →

Annual report FY2025 Revenue $502.73M up 27.8% 10-K filed Mar 12, 2026 Quarterly report FY2026 Q3 Revenue $169.77M up 24.3% 10-Q filed Nov 6, 2026 Latest results Revenue rises 24.3% as Adjusted EBITDA turns positive 8-K filed Nov 5, 2026 Earnings call Q2 2026 earnings call Held Aug 6, 2026
2026
Nov 12
Current report 8-K/A
FY26 revenue guided to $650 – 660M; adjusted EBITDA $4 – 6M

Starling Oncology projects FY26 revenue of $650 – 660M and FY26 Adj. EBITDA of $4 – 6M, after 3Q26 revenue of $170M increased 24% YoY and Adj EBITDA reached $3.4M.

Regulation FD disclosure
4 source passages
$650 – 660M FY26 Revenue $4 – 6M FY26 Adj. EBITDA 3Q26 Revenue of $170M increased 24% YoY Adj EBITDA of $3.4M Starling Oncology, Inc. (the “Company”) has prepared an updated investor presentation (the “Investor Presentation”) to use in meetings with investors. Open the document at this passage
Nov 12
Current report 8-K
FY26 revenue guidance reaches $650 – 660M

Starling Oncology forecasts FY26 revenue of $650 – 660M and Adjusted EBITDA of $4 – 6M; 3Q26 revenue increased 24% YoY to $170M, with Adjusted EBITDA of $3.4M.

Regulation FD disclosure
4 source passages
Starling Oncology | Investor Presentation Disclaimer $650 – 660M FY26 Revenue $4 – 6M FY26 Adj. EBITDA 3Q26 Revenue of $170M increased 24% YoY Adj EBITDA of $3.4M Open the document at this passage
Nov 6
Quarterly report 10-Q FY2026 Q3, ended Sep 30
Third-quarter revenue rose 24.3%, but net loss persisted

Starling Oncology reported third-quarter revenue of $169,767 and net loss of $(15,748), with figures in thousands; Adjusted EBITDA was $3,394. At September 30, 2026, cash was $36,895, and management expected liquidity for at least one year.

Revenue $169.77M ▲ 24.3% Net loss $15.75M Diluted EPS -$0.13
Read from the MD&A section
6 source passages
references to Starling Oncology, Inc., a Delaware corporation (“STLN”) Total operating revenue | 169,767 | 136,564 | 33,203 | 24.3% | 478,490 | 360,772 | 117,718 | 32.6% Net loss | (15,748) | (16,504) | 756 | (4.6)% | (28,029) | (53,098) | 25,069 | (47.2)% Adjusted EBITDA | 3,394 | (3,459) | 6,853 | (198.1)% | 1,185 | (12,555) | 13,740 | (109.4)% The Company had cash and cash equivalents of $36,895 and an accumulated deficit of $299,448 at September 30, 2026 The Company has concluded that it will have sufficient liquidity to fund its operations for at least one year from the date these consolidated financial statements are issued. Open the document at this passage
Nov 5
Current report 8-K
Revenue rises 24.3% as Adjusted EBITDA turns positive

Starling Oncology reported third-quarter revenue of $169.8 million, up 24.3% year over year, and Adjusted EBITDA of positive $3.4 million. It updated fiscal-year 2026 revenue guidance to $650 to $660 million and Adjusted EBITDA guidance to $4 to $6 million.

Financial results
5 source passages
Starling Oncology Reports Third Quarter 2026 Financial Results and Updates Full-Year 2026 Guidance Consolidated revenue of $169.8 million increased 24.3% from $136.6 million Adjusted EBITDA*\** of positive $3.4 million compared to $(3.5) million Revenue | $650 to $670 million | $650 to $660 million Adjusted EBITDA\** | $2 to $7 million | $4 to $6 million Open the document at this passage
Aug 6
Quarterly report 10-Q FY2026 Q2, ended Jun 30
Quarterly report for FY2026 Q2 AI summary on its way
Revenue $161.28M ▲ 34.6% Net loss $9.79M Diluted EPS -$0.08
May 7
Quarterly report 10-Q FY2026 Q1, ended Mar 31
Quarterly report for FY2026 Q1 AI summary on its way
Revenue $147.44M ▲ 41.2% Net loss $2.49M Diluted EPS -$0.02
Apr 30
Proxy statement DEF 14A Meeting Jun 17, 2026
Proxy statement AI summary on its way
Mar 12
Annual report 10-K FY2025, ended Dec 31
Annual report for FY2025 AI summary on its way
Revenue $502.73M ▲ 27.8% Net loss $60.61M Diluted EPS -$0.54
2025
Showing 1–50 of 170 documents
Key facts CIK 1799191 CUSIP 68236X100 13F (30d) 140 filings 127 filers Visit website Investor relations